Key facts
- This page summarizes Novo Holdings A/S's Form 4 filing for Hemab Therapeutics Holdings, Inc. (COAG).
- 5 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 06 May 2026, 16:55.
Novo Holdings A/S - 04 May 2026 Form 4 Insider Report for Hemab Therapeutics Holdings, Inc. (COAG)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- COAG
- Reported as of
- 04 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 May 2026, 16:55:22 UTC
- Prior SEC filing
- 05 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Barbara Fiorini, General Counsel, Finance & Operations of Novo Holdings A/S
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Novo Holdings A/S filed Form 4 for Hemab Therapeutics Holdings, Inc. (COAG) on 06 May 2026.
Change
- Previous filing in this sequence was filed on 05 May 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001388325
Primary reporting owner
Novo Holdings A/S
- Relationship
- 10%+ Owner
- Address
- TUBORG HAVNEVEJ 19, HELLERUP, DENMARK
- Signature
- /s/ Barbara Fiorini, General Counsel, Finance & Operations of Novo Holdings A/S
- Signature date
- 06 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
COAG
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +4,180,550
- Change %
- Price
- Shares after
- 4,180,550
- Date
- 04 May 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
COAG
transaction
Derivative
Series Seed Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -23,343
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 04 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 513,546
- Exercise price
- Footnotes
- F1
COAG
transaction
Derivative
Series A Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -71,866
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 04 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,581,052
- Exercise price
- Footnotes
- F1
COAG
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -62,121
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 04 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,366,662
- Exercise price
- Footnotes
- F1
COAG
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -32,695
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 04 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 719,290
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Novo Holdings A/S is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.